These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 13418)

  • 1. Clinical investigations for emotional effects of neuropeptide hormones.
    Ehrensing RH; Kastin AJ
    Pharmacol Biochem Behav; 1976; 5(Suppl 1):89-93. PubMed ID: 13418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-related biphasic effect of prolyl-leucyl-glycinamide (MIF-I) in depression.
    Ehrensing RH; Kastin AJ
    Am J Psychiatry; 1978 May; 135(5):562-6. PubMed ID: 25588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in major depression after low subcutaneous doses of MIF-1.
    Ehrensing RH; Kastin AJ; Wurzlow GF; Michell GF; Mebane AH
    J Affect Disord; 1994 Aug; 31(4):227-33. PubMed ID: 7989637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double blind cross over trial of gonadotrophin releasing hormone (LHRH) in sexually impotent men.
    Davies TF; Mountjoy CQ; Gomez-Pan A; Watson MJ; Hanker JP; Besser GM; Hall R
    Clin Endocrinol (Oxf); 1976 Nov; 5(6):601-7. PubMed ID: 795564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropharmacological studies with thyrotropin releasing hormone (TRH) and other hypothalamic hormones.
    Kruse H
    Naunyn Schmiedebergs Arch Pharmacol; 1977; 297 Suppl 1():S61-2. PubMed ID: 16226
    [No Abstract]   [Full Text] [Related]  

  • 6. Behavioral effects of hypothalamic releasing hormones in animals and men.
    Prange AJ; Wilson IC; Breese GR; Lipton MA
    Prog Brain Res; 1975; 42():1-9. PubMed ID: 729
    [No Abstract]   [Full Text] [Related]  

  • 7. Peptide challenges in affective illness.
    Cohen RM; Cohen MR
    J Clin Psychopharmacol; 1981 Jul; 1(4):214-22. PubMed ID: 6117586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The influence of MIF (melanocyte-stimulating hormone-release inhibiting factor) on psychomotor function and mood in parkinsonian patients. Preliminary report (author's transl)].
    Schneider E; Fischer PA; Jacobi P; Reh W
    Arzneimittelforschung; 1978; 28(8):1296-7. PubMed ID: 37848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of endogenous depressions with thyrotropin-releasing hormone (TRH) under oral administration.
    Schmidt J
    Acta Psychiatr Scand; 1977 Feb; 55(2):142-6. PubMed ID: 402795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of thyrotropin-releasing hormone with melanocyte-stimulating-hormone-release-inhibiting factor as pentobarbital antagonists in monkeys.
    Crowley TJ; Hydinger M
    Psychopharmacology (Berl); 1977 Jul; 53(2):205-6. PubMed ID: 19803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIF, TRH, and simian social and motor behavior.
    Crowley TJ; Hydinger M
    Pharmacol Biochem Behav; 1976; 5(Suppl 1):79-87. PubMed ID: 13417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRH in depressive illness.
    Pecknold JC; Ban TA
    Int Pharmacopsychiatry; 1977; 12(3):166-73. PubMed ID: 410749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of LHRH and TRH on human interferon-gamma production in vivo and in vitro.
    Grasso G; Massai L; De Leo V; Muscettola M
    Life Sci; 1998; 62(22):2005-14. PubMed ID: 9627099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurologically active peptides.
    Barbeau A; Gonce M; Kastin AJ
    Pharmacol Biochem Behav; 1976; 5(Suppl 1):159-63. PubMed ID: 13415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral and hormonal effects of prolonged high doses of LHRH in male impotency.
    Ehrensing RH; Kastin AJ; Schally AV
    Peptides; 1981; 2 Suppl 1():115-21. PubMed ID: 7022397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotropic and pituitary effects of melanostatin (MIF), thyroliberin (TRH) and structurally related peptides.
    Björkman S
    Acta Pharm Suec; 1980; 17(6):352. PubMed ID: 6111892
    [No Abstract]   [Full Text] [Related]  

  • 17. CNS and pituitary effects of hypothalamic peptides and MSH.
    Kastin AJ; Miller LH; Sandman CA; Schally AV; Plotnikoff NP
    Essays Neurochem Neuropharmacol; 1977; 1():139-76. PubMed ID: 30623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II.
    Huidobro-Toro JP; Scotti de Carolis A; Longo VG
    Pharmacol Biochem Behav; 1975; 3(2):235-42. PubMed ID: 238221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral administration of hypothalamic peptides results in CNS changes.
    Kastin AJ; Coy DH; Schally AV; Miller LH
    Pharmacol Res Commun; 1978 Apr; 10(4):293-312. PubMed ID: 28532
    [No Abstract]   [Full Text] [Related]  

  • 20. Commentary: Neuropharmacology of hypothalamic releasing factors.
    Plotnikoff NP; Kastin AJ
    Biochem Pharmacol; 1976 Feb; 25(4):363-5. PubMed ID: 7268
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.